A detailed history of Ubs Oconnor LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 25,000 shares of RARE stock, worth $1.14 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
25,000
Holding current value
$1.14 Million
% of portfolio
0.1%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.21 - $59.36 $557,270 - $822,670
-13,859 Reduced 39.45%
21,269 $1.18 Million
Q2 2024

Aug 14, 2024

SELL
$37.42 - $51.61 $279,826 - $385,939
-7,478 Reduced 17.55%
35,128 $1.44 Million
Q1 2024

May 15, 2024

SELL
$43.02 - $53.69 $617,337 - $770,451
-14,350 Reduced 25.19%
42,606 $1.99 Million
Q4 2023

Feb 14, 2024

SELL
$31.73 - $49.19 $633,299 - $981,783
-19,959 Reduced 25.95%
56,956 $2.72 Million
Q3 2023

Nov 14, 2023

BUY
$34.92 - $46.66 $334,079 - $446,396
9,567 Added 14.21%
76,915 $2.74 Million
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $2.52 Million - $3.51 Million
67,348 New
67,348 $3.11 Billion
Q1 2023

May 15, 2023

BUY
$36.99 - $48.71 $359,801 - $473,802
9,727 Added 19.63%
59,276 $2.38 Million
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $1.67 Million - $2.3 Million
49,549 New
49,549 $0

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.18B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.